全文获取类型
收费全文 | 5523篇 |
免费 | 309篇 |
国内免费 | 34篇 |
专业分类
耳鼻咽喉 | 71篇 |
儿科学 | 138篇 |
妇产科学 | 162篇 |
基础医学 | 703篇 |
口腔科学 | 146篇 |
临床医学 | 373篇 |
内科学 | 1437篇 |
皮肤病学 | 110篇 |
神经病学 | 515篇 |
特种医学 | 142篇 |
外科学 | 918篇 |
综合类 | 31篇 |
预防医学 | 318篇 |
眼科学 | 81篇 |
药学 | 233篇 |
中国医学 | 15篇 |
肿瘤学 | 473篇 |
出版年
2023年 | 49篇 |
2022年 | 87篇 |
2021年 | 285篇 |
2020年 | 120篇 |
2019年 | 217篇 |
2018年 | 229篇 |
2017年 | 165篇 |
2016年 | 138篇 |
2015年 | 143篇 |
2014年 | 226篇 |
2013年 | 291篇 |
2012年 | 460篇 |
2011年 | 521篇 |
2010年 | 262篇 |
2009年 | 239篇 |
2008年 | 357篇 |
2007年 | 364篇 |
2006年 | 345篇 |
2005年 | 327篇 |
2004年 | 256篇 |
2003年 | 240篇 |
2002年 | 208篇 |
2001年 | 28篇 |
2000年 | 28篇 |
1999年 | 44篇 |
1998年 | 43篇 |
1997年 | 28篇 |
1996年 | 15篇 |
1995年 | 20篇 |
1994年 | 14篇 |
1993年 | 18篇 |
1992年 | 13篇 |
1991年 | 11篇 |
1990年 | 7篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1987年 | 4篇 |
1986年 | 4篇 |
1984年 | 6篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1981年 | 9篇 |
1980年 | 3篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1974年 | 2篇 |
1973年 | 2篇 |
1920年 | 1篇 |
排序方式: 共有5866条查询结果,搜索用时 31 毫秒
991.
Aranda F Llopiz D Díaz-Valdés N Riezu-Boj JI Bezunartea J Ruiz M Martínez M Durantez M Mansilla C Prieto J Lasarte JJ Borrás-Cuesta F Sarobe P 《Cancer research》2011,71(9):3214-3224
Low antigen expression and an absence of coimmunostimulatory signals may be partly responsible for the low immunogenicity of many tumors. It may be possible to overcome this situation by defining a combination of adjuvants and antigens that can activate a high-avidity antitumor response. Using the poorly immunogenic B16-OVA melanoma cells as tumor model, we tested different combinations of adjuvants and antigens to treat established tumors. In the absence of exogenous antigens, repeated administration of the TLR7 ligand Imiquimod together with anti-CD40 agonistic antibodies activated only innate immunity, which was insufficient to reject intradermal tumors. Administering this adjuvant combination together with OVA as a tumor antigen induced T-cell responses that delayed tumor growth. However, administering a combination of anti-CD40 plus TLR3 and TLR7 ligands, together with antigen targeting to dendritic cells through TLR4, was sufficient to induce tumor rejection in 50% of mice. This response was associated with a greater activation of innate immunity and induction of high-avidity polyfunctional CD8(+) T-cell responses, which each contributed to tumor rejection. This therapy activated T-cell responses not only against OVA, which conferred protection against a rechallenge with B16-OVA cells, but also activated T-cell responses against other melanoma-associated antigens. Our findings support the concept that multiple adjuvant combination and antigen targeting may be a useful immunotherapeutic strategy against poorly immunogenic tumors. 相似文献
992.
Damelin M Geles KG Follettie MT Yuan P Baxter M Golas J DiJoseph JF Karnoub M Huang S Diesl V Behrens C Choe SE Rios C Gruzas J Sridharan L Dougher M Kunz A Hamann PR Evans D Armellino D Khandke K Marquette K Tchistiakova L Boghaert ER Abraham RT Wistuba II Zhou BB 《Cancer research》2011,71(12):4236-4246
Poorly differentiated tumors in non-small cell lung cancer (NSCLC) have been associated with shorter patient survival and shorter time to recurrence following treatment. Here, we integrate multiple experimental models with clinicopathologic analysis of patient tumors to delineate a cellular hierarchy in NSCLC. We show that the oncofetal protein 5T4 is expressed on tumor-initiating cells and associated with worse clinical outcome in NSCLC. Coexpression of 5T4 and factors involved in the epithelial-to-mesenchymal transition were observed in undifferentiated but not in differentiated tumor cells. Despite heterogeneous expression of 5T4 in NSCLC patient-derived xenografts, treatment with an anti-5T4 antibody-drug conjugate resulted in complete and sustained tumor regression. Thus, the aggressive growth of heterogeneous solid tumors can be blocked by therapeutic agents that target a subpopulation of cells near the top of the cellular hierarchy. 相似文献
993.
Blanco B Sánchez-Abarca LI Caballero-Velázquez T Santamaría C Inogés S Pérez-Simón JA 《Leukemia research》2011,35(10):1412-1415
Current graft-versus-host disease (GVHD) inhibition approaches lead to abrogation of pathogen-specific T-cell responses. We propose an approach to inhibit GVHD without hampering immunity against pathogens: in vitro depletion of alloreactive T cells with the preoteasome inhibitor bortezomib. We show that PBMCs stimulated with allogeneic cells and treated with bortezomib greatly reduce their ability to produce IFN-γ when re-stimulated with the same allogeneic cells, but mainly preserve their ability to respond to citomegalovirus stimulation. Unlike in vivo administration of immunosuppressive drugs or other strategies of allodepletion, in vitro allodepletion with bortezomib maintains pathogen-specific T cells, representing a promising alternative for GVHD prophylaxis. 相似文献
994.
995.
Bonifaci N Palafox M Pellegrini P Osorio A Benítez J Peterlongo P Manoukian S Peissel B Zaffaroni D Roversi G Barile M Viel A Mariette F Bernard L Radice P Kaufman B Laitman Y Milgrom R Friedman E Sáez ME Climent F Soler MT Diez O Balmaña J Lasa A Ramón y Cajal T Miramar MD de la Hoya M Pérez-Segura P Caldés T Moreno V Urruticoechea A Brunet J Lázaro C Blanco I Pujana MA González-Suárez E 《Breast cancer research and treatment》2011,129(3):947-954
Intracellular signaling mediated by the receptor activator of nuclear factor-κB [Rank, encoded by the tumor necrosis factor receptor superfamily, member 11a (Tnfrsf11a) gene] is fundamental for mammary gland development in mice, regulating the expansion of stem and progenitor cell compartments. Conversely, Rank overexpression in mice promotes abnormal proliferation and impairs differentiation, leading to an increased incidence of tumorigenesis. Here, we show that a common genetic variant near the 5'-end of TNFRSF11A, rs7226991, is associated with breast cancer risk in the general population and among carriers of mutations in the breast cancer 2, early onset (BRCA2) gene. Akin to the results of the Cancer and Genetics Markers of Susceptibility initiative, combined analysis of rs7226991 in two Spanish case-control studies (1,365 controls and 1,323 cases in total) revealed a significant association with risk: odds ratio (OR) = 0.88, 95% confidence interval (CI) 0.78-0.98, P (trend) = 0.025. Subsequent examination of BRCA1 (n = 1,017) and BRCA2 (n = 885) mutation carriers revealed a consistent association in the latter group: weighted hazard ratio ((w)HR) = 0.70; 95% CI 0.55-0.88; and P (trend) = 0.003; compared to BRCA1 mutation carriers, (w)HR = 0.91; 95% CI 0.76-1.10; and P (trend) = 0.33. The results of this study need to be replicated in other populations and with larger numbers of BRCA1/2 mutation carriers. 相似文献
996.
David J. Stewart Carmen BehrensJack Roth Ignacio I. Wistuba 《Lung cancer (Amsterdam, Netherlands)》2011,71(2):217-223
Background
For processes that follow first order kinetics, exponential decay nonlinear regression analysis (EDNRA) may delineate curve characteristics and suggest processes affecting curve shape. We conducted a preliminary feasibility assessment of EDNRA of patient survival curves.Methods
EDNRA was performed on Kaplan-Meier overall survival (OS) and time to relapse (TTR) curves for 323 patients with resected NSCLC and on OS and progression-free survival (PFS) curves from selected publications.Results and conclusions
In our resected patients, TTR curves were triphasic with a “cured” fraction of 60.7% (half-life [t1/2] >100,000 months), a rapidly relapsing group (7.4%, t1/2 = 5.9 months) and a slowly relapsing group (31.9%, t1/2 = 23.6 months). OS was uniphasic (t1/2 = 74.3 months), suggesting an impact of co-morbidities; hence, tumor molecular characteristics would more likely predict TTR than OS. Of 172 published curves analyzed, 72 (42%) were uniphasic, 92 (53%) were biphasic, 8 (5%) were triphasic. With first-line chemotherapy in advanced NSCLC, 87.5% of curves from 2 to 3 drug regimens were uniphasic vs. only 20% of those with best supportive care or 1 drug (p < 0.001). 54% of curves from 2 to 3 drug regimens had convex rapid-decay phases vs. 0% with fewer agents (p < 0.001). Curve convexities suggest that discontinuing chemotherapy after 3-6 cycles “synchronizes” patient progression and death. With postoperative adjuvant chemotherapy, the PFS rapid-decay phase accounted for a smaller proportion of the population than in controls (p = 0.02) with no significant difference in rapid-decay t1/2, suggesting adjuvant chemotherapy may move a subpopulation of patients with sensitive tumors from the relapsing group to the cured group, with minimal impact on time to relapse for a larger group of patients with resistant tumors. In untreated patients, the proportion of patients in the rapid-decay phase increased (p = 0.04) while rapid-decay t1/2 decreased (p = 0.0004) with increasing stage, suggesting that higher stage may be associated with tumor cells that both grow more rapidly and have a higher probability of surviving metastatic processes than in early stage tumors.This preliminary assessment of EDNRA suggests that it may be worth exploring this approach further using more sophisticated, statistically rigorous nonlinear modelling approaches. Using such approaches to supplement standard survival analyses could suggest or support specific testable hypotheses. 相似文献997.
998.
999.
Ben Saïd M Ayedi L Mnejja M Hakim B Khalfallah A Charfeddine I Khifagi C Turki K Ayadi H Benzina Z Ghorbel A Castillo ID Masmoudi S Aifa MH 《European journal of medical genetics》2011,54(6):e535-e541
Autosomal recessive non-syndromic hearing loss (ARNSHL) is a genetically heterogenous disorder with 41 genes so far identified. Among these genes, ESRRB whose mutations are responsible for DFNB35 hearing loss in Pakistani and Turkish families. This gene encodes the estrogen-related receptor beta. In this study, we report a novel mutation (p.Y305H) in the ESRRB gene in a Tunisian family with ARNSHL. This mutation was not detected in 100 healthy individuals. Molecular modeling showed that the p.Y305H mutation is likely to alter the conformation of the ligand binding-site by destabilizing the coactivator binding pocket. Interestingly, this ligand-binding domain of the ESRRB protein has been affected in 5 out of 6 mutations causing DFNB35 hearing loss. Using linkage and DHPLC analysis, no more mutations were detected in the ESRRB gene in other 127 Tunisian families with ARNSHL indicating that DFNB35 is most likely to be a rare type of ARNSHL in the Tunisian population. 相似文献
1000.
Bensaïd M Hmani-Aifa M Hammami B Tlili A Hakim B Charfeddine I Ayadi H Ghorbel A Castillo ID Masmoudi S 《European journal of medical genetics》2011,54(6):e565-e569
We previously mapped the DFNB66 locus to an interval overlapping the DFNB67 region. Mutations in the LHFPL5 gene were identified as a cause of DFNB67 hearing loss (HL). However, screening of the coding exons of LHFPL5 did not reveal any mutation in the DFNB66 family. The objective of this study was to check whether DFNB66 and DFNB67 are distinctive loci and determining their contribution to HL. In the DFNB66 family, sequencing showed absence of mutations in the untranslated regions and the predicted promoter sequence of LHFPL5. Analysis of five microsatellites in the 6p21.31–22.3 region and screening of the LHFPL5 gene by DNA heteroduplex analysis in DHPLC revealed a novel mutation (c.89dup) in one out of 129 unrelated Tunisian families with autosomal recessive nonsyndromic (ARNS) HL. Our findings suggest that two distinct genes are responsible for DFNB66 and DFNB67 HL. These loci are likely to be a rare cause of ARNSHL. 相似文献